Anti-helicobacter Pylori Treatment CAN Effectively Improve The Clinical Remission Rate Of Irritable Bowel Syndrome Patients: A Metaanalysis Based On Clinical Controlled Trials

Objectiveby exploring the different clinical remission rate between with anti-helicobacter pylori treatment and with not that in IBS patients with helicobacter pylori infection,to provide more clinical evidences for a new treatment point for IBS patients.MethodsRelevant studies were searched in electronic database:Pubmed,Embase,the Cochrane Central Register of Controlled Trials,CNKI,CBM,Wanfang and VIP by using "helicobacter pylori","irritable bowel syndrome" and "control" as search terms.The literature was screened according to relatively strict inclusion and exclusion criteria.Revman 5.3.5 and Stata 15.1 software were used for meta analysis,assessment of publication bias and sensitivity analysis.ResultsTotal of 10 studies were included in our article,including 655 patients with irritable bowel syndrome and helicobacter pylori infection,385 patients in the experimental group and 270 patients in the control group.Meta analysis showed that OR=2.87,95%CI 1.74-4.72,P < 0.0001.Funnel plot showed that the publication bias was small,and the sensitivity analysis suggested that the research results were stable and reliable.ConclusionHelicobacter pylori infection is related to the incidence of irritable bowel syndrome.Anti-helicobacter pylori treatment can effectively improve the clinical remission rate of irritable bowel syndrome patients.Whether it means that patients with irritable bowel syndrome should be given actively anti-infection treatment as a new therapy to effectively improve the clinical symptom remission rate.